Hanmi to Present Phase 2 Data of EPeglucoagon (HM15136) for CHI at ESPE 2026

Hanmi Pharmaceutical announced that it will present the global Phase 2 clinical study results of EPeglucoagon (HM15136), its investigational treatment for congenital hyperinsulinism (CHI), at the 64th European Society for Paediatric Endocrinology (ESPE) conference in Marseille, France. The Phase 2 trial has completed its core dosing period, and the forthcoming data analysis will be a pivotal decision point for the program’s further development. EPeglucoagon is being developed as the world’s first once‑weekly formulation for patients with CHI. The presentation is scheduled for 8–10 May 2026 (local time) during the ESPE meeting.